Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Lee YJ, Kim JM, Park JY, Kim YJ, Kim Y. [Cost-effectiveness of human papillomavirus vaccination in South Korea] Seoul: National Evidence-based Healthcare Collaborating Agency (NECA). NECA-A-12-002. 2013 Authors' objectives The purpose of this study is to provide evidence for rational decision making through conducting the economic evaluation of HPV vaccine by societal perspective. Authors' conclusions Based on the assumption that the cost of the vaccine after introduction of the vaccination program would decrease to 70% of its current price, the incremental cost-effectiveness ratio of the vaccination of 13-year-old girls was $32,000 per quality-adjusted life-year (QALY) gained, as compared with the current screening practice. Therefore, the vaccination program is not cost-effective in Korea given the cost-effectiveness threshold of GDP per capita ($23,680). The sensitivity analysis showed that the price, the effectiveness of vaccination and discount rate affected the result. Indexing Status Subject indexing assigned by CRD MeSH Cost-Benefit Analysis; Humans; Korea; Papillomavirus Infections; Papillomavirus Vaccines Country of organisation South Korea English summary An English language summary is available. Address for correspondence National Evidence-based Healthcare Collaborating Agency (NECA), Changkyung B/D 9F, Wonnam-dong 28-7, Jongno-gu, Seoul, South Korea
Email: hta_neca@neca.re.kr AccessionNumber 32013000523 Date abstract record published 22/07/2013 |